Axonics Modulation Technologies Raises $32.6M in Series A Financing

Axonics Modulation Technologies, a developer of implantable neuromodulation technology, announced that it has completed a $32.6 million Series A preferred stock financing.

Advertisement

The financing will provide capital to accelerate product development and fund a series of multicenter clinical studies to establish safety and efficacy of the company’s patented neuromodulation system.

More Articles on Devices:

Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.